Biomark Capital
VC Fund
San Francisco, United States
Biomark Capital is a VC fund in San Francisco focused on Health Care and Medical. Biomark Capital provides venture funding and assistance to early, mid, and late-stage life science companies. We target companies with novel approaches to diagnostics, therapeutics, medical devices, and digital health that will change the face of healthcare innovation in the future. We share the drive and vision of our portfolio companies tocollaborate with them in accelerating growth and building successful business ventures.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 0%
- Fund size:
- $191M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Biomark Capital invests in
Stages Biomark Capital invests in
Countries Biomark Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 7 contacts → | |||
Investment Focus
Industry
- Health Care 5 (63%)
- Medical 3 (38%)
- Biotechnology 3 (38%)
- Health Diagnostics 2 (25%)
- Genetics 1 (13%)
Stage
- Funding Round 4 (50%)
- Series A 1 (13%)
- Series B 1 (13%)
- Series E 1 (13%)
- Post-IPO Equity 1 (13%)
Country
- United States 5 (63%)
- Taiwan 1 (13%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Anna G. Annenko
Director
|
Director | Total investments: 0 | Find email | |
Bryant E. Fong
Managing Director
|
Managing Director | Total investments: 12 | Find email | |
David Wetherell
Founder & Managing Director
|
Founder & Managing Director | Total investments: 7 | Find email | |
Douglas Lind
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
Janos Redei
EIR
|
EIR | Total investments: 0 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Eden Biologics
|
Eden Biologics, formerly known as JHL Biotech ("JHL") , is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners through the provision of contract development and manufacturing services. We are specialists in manufacturing biologics, from cell line development tocommercial manufacturing with both global and regional regulatory affairs expertise. | $106M / Post-IPO Equity / May 29, 2018 | |
|
Eden Biologics
|
Eden Biologics, formerly known as JHL Biotech ("JHL") , is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners through the provision of contract development and manufacturing services. We are specialists in manufacturing biologics, from cell line development tocommercial manufacturing with both global and regional regulatory affairs expertise. | $35M / Series B / Jun 19, 2014 | |
|
Eden Biologics
|
Eden Biologics, formerly known as JHL Biotech ("JHL") , is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners through the provision of contract development and manufacturing services. We are specialists in manufacturing biologics, from cell line development tocommercial manufacturing with both global and regional regulatory affairs expertise. | Series A / Dec 17, 2012 | |
i2Dx
|
i2Dx is developing a multimodal, cloud-based diagnostic platform for the assessment of neurological disorders. The platform will provide quantitative digital assessments of a number of biomarkers that are indicative of brain health with the goal of providing a personalized, longitudinal brain record for healthy individuals and patients. | Jul 17, 2012 | |
WhiteGlove Health
|
WhiteGlove Health has become a leader in the healthcare industry through providing an extraordinary healthcare experience for members and providing significant cost savings for health plans through reduced insurance claims and reductions in unnecessary utilization. Their comprehensive healthcare strategy is to provide the highest quality care at apredictable cost through highly-skilled nurse practitioners supported by registered nurses in collaboration with physicians, hospitals, other health care providers and carriers.Since 2007, WhiteGlove Health’s highly trained and experienced clinical team comprised of board-certified Nurse Practitioners and Registered Nurses have been making house calls, office calls and providing telephonic support to help members feel better, faster. Their initial focus as a mobile healthcare provider for acute needs and managing chronic conditions has paved the way for the successful introduction of their Value-Based Care division in 2014 which leverages their clinical expertise and ability to deliver provider care to high risk/high cost patients for their Medicare and Medicaid health plan customers. Value-Based Care is conducted at-home or at a Skilled Nursing Facility (SNF) and allows health plans the ability to care for their most challenging patients.Their Solution offers care designed to reduce hospital admissions, re-admissions and prevent unnecessary visits to an emergency room. A WhiteGlove Health Nurse Practitioner has the ability to order or discontinue medications, add home health or durable medical Equipment (as needed) and routinely communicate with the Primary Care Physician on behalf of the patient. The WhiteGlove Health strategy of prompt follow-up and proactive intervention allows us to carefully monitor patients and manage utilization.In June 2014, WhiteGlove Health acquired Glenridge Healthcare Solutions, a leading consulting, technology and professional services firm, founded in 1997 and headquartered in Maryland. Together, their companies are creating more opportunities and efficiencies than they could have achieved independently. Glenridge continues to partner with customers nationwide by providing a seasoned team, advanced data analytic capabilities and state-of-the art technology to their established impressive portfolio. | $12.9M / Series E / Apr 12, 2012 | |
ADMA Biologics
|
ADMA is a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The Company’s target patient populations include immune-compromised individuals who suffer from an underlying immune deficiencydisease or who may be immune-suppressed for medical reasons.ADMA also operates ADMA BioCenters, FDA-licensed source plasma collection facilities which provide a portion of blood plasma for the manufacturing of the Company’s lead product candidate RI-002. | $17.5M / Feb 13, 2012 | |
HyperMed Imaging, Inc.
|
HyperMed is developing hyperspectral imaging for medical applications. The technology, originally developed for military surveillance, provides an advanced form of spectroscopy that provides a two-dimensional tissue oxygenation map. The company’s first product, OxyVu, was developed for the US research market and subsequently received FDA 510(k)approval for medical diagnostic applications where the measurement of microvasculature perfusion can assist physicians with patient care. Multiple published studies have demonstrated the clinical utility of OxyVu for the diagnostic assessment of wound healing, diabetic foot ulcers, and amputation planning. The market opportunity for the clinical diagnostic applications for hyperspectral imaging represent a multi-billion market. | Jan 02, 2012 | |
Lentigen
|
Lentigen Corporation, a biotechnology company, engages in the development and commercialization of gene delivery technologies for human disease. It provides lentiviral vector technology for a range of therapeutic, vaccine, and research applications in biotechnology and medicine. The company offers LG690, a cell therapy for treatment of graft vs hotdiseases; LG768, a cancer vaccine for the treatment of leukemia; stem cell therapy to prevent and treat medical disorders; LG631, a treatment that makes chemotheraphy for brain cancer less toxic; LG889, a steam cell therapy for hemophilia; LG611, an exact strain matched influenza vaccine for pandemic flu; LG811, an exact strain matched influenza vaccine for seasonal flu; LG747, a biosimilar erytho poieitin; and LG888, a novel factor VIII protein therapy for Hemophilia A. Lentigen Corporation was founded in 2004 and is headquartered in Gaithersburg, Maryland. | Jan 02, 2012 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Biomark Capital invest in?
Biomark Capital invests primarily in Health Care, Medical and Biotechnology startups, most often at Funding Round and Series A stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Biomark Capital?
Public channels for Biomark Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Biomark Capital?
The team at Biomark Capital includes Anna G. Annenko (Director), Bryant E. Fong (Managing Director) and David Wetherell (Founder & Managing Director), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
